Xeltis

Xeltis is a clinical-stage medical device company pioneering a novel approach to cardiovascular implants. Its core technology, Endogenous Tissue Restoration (ETR), utilizes a Nobel prize-winning supramolecular polymer scaffold that guides the body to regenerate a natural, living blood vessel or valve. The company's lead program, aXess, is a vascular access conduit for hemodialysis patients and has been implanted in over 180 patients, with the company securing significant funding in late 2025 to advance it toward the market. Xeltis aims to break the cycle of surgical complications and reinterventions associated with current synthetic and biological grafts.

Endogenous Tissue Restoration (ETR): A platform using supramolecular bioabsorbable polymer scaffolds that are implanted and gradually replaced by the patient's own living tissue, forming new blood vessels or valves.

Xeltis competes with large medical device companies offering synthetic (e.g., PTFE) and biological grafts for vascular access and bypass. Its primary differentiation is its restorative mechanism, aiming to reduce long-term complications. It also faces potential future competition from other regenerative medicine approaches, such as tissue-engineered vessels.